APCCC 2024 | Management of biochemical recurrence in prostate cancer

Jason Efstathiou, MD, DPhil, Harvard Medical School, Boston, MA, gives an overview of treatment strategies for biochemical recurrent prostate cancer, including the role of radiotherapy in treating pelvic lymph nodes. Prof. Efstathiou additionally comments on systemic therapies for high risk biochemical recurrent prostate cancer, and the EMBARK trial (NCT02319837) of enzalutamide monotherapy, or enzalutamide with leuprolide against placebo and leuprolide in this setting. This interview took place at the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.